Literature DB >> 22205538

The significance of Exonuclease 1 K589E polymorphism on hepatocellular carcinoma susceptibility in the Turkish population: a case-control study.

Süleyman Bayram1, Hikmet Akkız, Aynur Bekar, Ersin Akgöllü, Selçuk Yıldırım.   

Abstract

Exonuclease 1 (Exo 1) is an important nuclease involved in mismatch repair system that contributes to maintain genomic stability, to modulate DNA recombination, and to mediate cell cycle arrest. A guanine (G)/adenine (A) common single nucleotide polymorphism at first position of codon 589 in Exo 1 gene determines a glutamic acid (Glu, E) to lysine (Lys, K) (K589E) aminoacidic substitution which may alter cancer risk by influencing the activity of Exo 1 protein. Exo 1 K589E polymorphism has been studied in various cancers, but its association with hepatocellular carcinoma (HCC) has yet to be investigated. To determine the association of the Exo 1 K589E polymorphism with the risk of HCC development in a Turkish population, a hospital-based case-control study was designed consisting of 224 subjects with HCC and 224 cancer-free control subjects matched for age, gender, smoking and alcohol status. The genotype frequency of the Exo 1 K589E polymorphism was determined by using a polymerase chain reaction-restriction fragment length polymorphism assay. Our data shows that the Lys/Lys genotype of the Exo 1 K589E polymorphism is associated with increased risk of HCC development in this Turkish population [odds ratio (OR) = 2.15, 95% confidence interval (CI): 1.13-4.09, P = 0.02]. Furthermore, according to stratified analysis, a significant association was observed between the homozygote Lys/Lys genotype and HCC risk in the subgroups of male gender (OR = 2.67, 95% CI: 1.27-5.61, P = 0.009) and patients with non-viral-related HCC (OR = 3.14, 95% CI: 1.09-8.99, P = 0.03). Because our results suggest for the first time that the Lys/Lys homozygote genotype of Exo 1 K589E polymorphism may be a genetic susceptibility factor for HCC in the Turkish population, further independent studies are required to validate our findings in a larger series, as well as in patients of different ethnic origins.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22205538     DOI: 10.1007/s11033-011-1406-x

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  46 in total

1.  Interactions of Exo1p with components of MutLalpha in Saccharomyces cerevisiae.

Authors:  P T Tran; J A Simon; R M Liskay
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-31       Impact factor: 11.205

2.  Single nucleotide polymorphism seeking long term association with complex disease.

Authors:  Brian W Kirk; Matthew Feinsod; Reyna Favis; Richard M Kliman; Francis Barany
Journal:  Nucleic Acids Res       Date:  2002-08-01       Impact factor: 16.971

3.  Identification and characterization of Saccharomyces cerevisiae EXO1, a gene encoding an exonuclease that interacts with MSH2.

Authors:  D X Tishkoff; A L Boerger; P Bertrand; N Filosi; G M Gaida; M F Kane; R D Kolodner
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-08       Impact factor: 11.205

Review 4.  DNA mismatch repair: functions and mechanisms.

Authors:  Ravi R Iyer; Anna Pluciennik; Vickers Burdett; Paul L Modrich
Journal:  Chem Rev       Date:  2006-02       Impact factor: 60.622

5.  Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions.

Authors:  Vassilis G Gorgoulis; Leandros-Vassilios F Vassiliou; Panagiotis Karakaidos; Panayotis Zacharatos; Athanassios Kotsinas; Triantafillos Liloglou; Monica Venere; Richard A Ditullio; Nikolaos G Kastrinakis; Brynn Levy; Dimitris Kletsas; Akihiro Yoneta; Meenhard Herlyn; Christos Kittas; Thanos D Halazonetis
Journal:  Nature       Date:  2005-04-14       Impact factor: 49.962

6.  DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis.

Authors:  Jirina Bartkova; Zuzana Horejsí; Karen Koed; Alwin Krämer; Frederic Tort; Karsten Zieger; Per Guldberg; Maxwell Sehested; Jahn M Nesland; Claudia Lukas; Torben Ørntoft; Jiri Lukas; Jiri Bartek
Journal:  Nature       Date:  2005-04-14       Impact factor: 49.962

7.  Identification of factors interacting with hMSH2 in the fetal liver utilizing the yeast two-hybrid system. In vivo interaction through the C-terminal domains of hEXO1 and hMSH2 and comparative expression analysis.

Authors:  L J Rasmussen; M Rasmussen; B Lee; A K Rasmussen; D M Wilson; F C Nielsen; H C Bisgaard
Journal:  Mutat Res       Date:  2000-06-30       Impact factor: 2.433

8.  Hex1: a new human Rad2 nuclease family member with homology to yeast exonuclease 1.

Authors:  D M Wilson; J P Carney; M A Coleman; A W Adamson; M Christensen; J E Lamerdin
Journal:  Nucleic Acids Res       Date:  1998-08-15       Impact factor: 16.971

Review 9.  The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma.

Authors:  Josep M Llovet; Josep Fuster; Jordi Bruix
Journal:  Liver Transpl       Date:  2004-02       Impact factor: 5.799

10.  Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production.

Authors:  Willscott E Naugler; Toshiharu Sakurai; Sunhwa Kim; Shin Maeda; Kyounghyun Kim; Ahmed M Elsharkawy; Michael Karin
Journal:  Science       Date:  2007-07-06       Impact factor: 47.728

View more
  13 in total

1.  A meta-analysis of the relationship between glutathione S-transferases gene polymorphism and hepatocellular carcinoma in Asian population.

Authors:  Jie Chen; Liang Ma; Ning-Fu Peng; Shi-Jun Wang; Le-Qun Li
Journal:  Mol Biol Rep       Date:  2012-10-10       Impact factor: 2.316

2.  Genetic risk of lung cancer associated with a single nucleotide polymorphism from EXO1: a meta analysis.

Authors:  Jian Tang; Shengbo Tang; Jichun Liu; Qicai Wu; Li Wan; Qirong Xu
Journal:  Int J Clin Exp Med       Date:  2015-07-15

3.  EXO1 overexpression is associated with poor prognosis of hepatocellular carcinoma patients.

Authors:  Yaoyao Dai; Zuxiong Tang; Zongguo Yang; Lan Zhang; Qing Deng; Xiaofeng Zhang; Yongchun Yu; Xing Liu; Junfeng Zhu
Journal:  Cell Cycle       Date:  2018-10-20       Impact factor: 4.534

4.  Bioinformatics Analysis and Experimental Study of Exonuclease 1 Gene in Lung Adenocarcinoma.

Authors:  Shan Wang; Weiguo Cai; Jianyu Li; Wenting An; Hui Zheng; Meiyan Liao
Journal:  Biochem Genet       Date:  2022-02-15       Impact factor: 1.890

5.  Associations between Nine Polymorphisms in EXO1 and Cancer Susceptibility: A Systematic Review and Meta-Analysis of 39 Case-control Studies.

Authors:  Meng Zhang; Duran Zhao; Cunye Yan; Li Zhang; Chaozhao Liang
Journal:  Sci Rep       Date:  2016-07-08       Impact factor: 4.379

6.  Association between three exonuclease 1 polymorphisms and cancer risks: a meta-analysis.

Authors:  Zi-Yu Chen; Si-Rong Zheng; Jie-Hui Zhong; Xiao-Duan Zhuang; Jue-Yu Zhou
Journal:  Onco Targets Ther       Date:  2016-02-23       Impact factor: 4.147

7.  Association between the C.1161G>A and C.1779C>G genetic variants of XRCC1 gene and hepatocellular carcinoma risk in Chinese population.

Authors:  Xin Deng; Jian Liang; Majun Jiang; Xiaoxiao Zhou; Hongdan Liu
Journal:  Int J Biol Sci       Date:  2013-03-07       Impact factor: 6.580

Review 8.  Involvement of DNA damage response pathways in hepatocellular carcinoma.

Authors:  Sheau-Fang Yang; Chien-Wei Chang; Ren-Jie Wei; Yow-Ling Shiue; Shen-Nien Wang; Yao-Tsung Yeh
Journal:  Biomed Res Int       Date:  2014-04-28       Impact factor: 3.411

9.  The significance of Exo1 K589E polymorphism on cancer susceptibility: evidence based on a meta-analysis.

Authors:  Fujiao Duan; Chunhua Song; Liping Dai; Shuli Cui; Xiaoqin Zhang; Xia Zhao
Journal:  PLoS One       Date:  2014-05-08       Impact factor: 3.240

10.  Transcriptome sequencing identified hub genes for hepatocellular carcinoma by weighted-gene co-expression analysis.

Authors:  Qi Pan; Xianli Long; Liting Song; Dachun Zhao; Xiaoyuan Li; Dewei Li; Min Li; Jiahua Zhou; Xia Tang; Hong Ren; Keyue Ding
Journal:  Oncotarget       Date:  2016-06-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.